BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 37970190)

  • 1. 5-fluorouracil therapeutic drug monitoring and adverse events in a Romanian population.
    Deac AL; Pop RM; Burz CC; Bocşan IC; Militaru C; Suciu Ş; Buzoianu AD
    Med Pharm Rep; 2023 Oct; 96(4):413-419. PubMed ID: 37970190
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Correlation between pharmacokinetic parameters of 5-fluorouracil and related metabolites and adverse reactions in East-Asian patients with advanced colorectal cancer.
    Tong Z; Cheng M; Yu Y; Yu J; Yin Y; Liu J; Zhang S; Jiang S; Dong M
    Cancer Chemother Pharmacol; 2022 Mar; 89(3):323-330. PubMed ID: 35067736
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Improving safety of fluoropyrimidine chemotherapy by individualizing treatment based on dihydropyrimidine dehydrogenase activity - Ready for clinical practice?
    Meulendijks D; Cats A; Beijnen JH; Schellens JH
    Cancer Treat Rev; 2016 Nov; 50():23-34. PubMed ID: 27589829
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical Benefit of Therapeutic Drug Monitoring in Colorectal Cancer Patients Who Received Fluorouracil-Based Chemotherapy.
    Zhou X; Chang Y; Qian J; Shen C; Han J; Zhao H; Chang R
    Med Sci Monit; 2021 Jul; 27():e929474. PubMed ID: 34330885
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A pharmacokinetic-based test to prevent severe 5-fluorouracil toxicity.
    Bocci G; Barbara C; Vannozzi F; Di Paolo A; Melosi A; Barsanti G; Allegrini G; Falcone A; Del Tacca M; Danesi R
    Clin Pharmacol Ther; 2006 Oct; 80(4):384-95. PubMed ID: 17015056
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Oral versus intravenous fluoropyrimidines for colorectal cancer.
    Chionh F; Lau D; Yeung Y; Price T; Tebbutt N
    Cochrane Database Syst Rev; 2017 Jul; 7(7):CD008398. PubMed ID: 28752564
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A retrospective analysis of plasma concentration monitoring of fluorouracil in patients with advanced colorectal cancer.
    Yang Q; Bi Y; Li X; Liu Q; Ma J; Zhang C; Zhang J; He G
    Eur J Hosp Pharm; 2020 Mar; 27(e1):e36-e40. PubMed ID: 32296503
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Incidence of Hematological Toxicities in Colorectal Cancer Patients Treated With Fluoropyrimidine-Based Regimens at Princess Noorah Oncology Center.
    Khan M; Alharbi S; Aljuhani S; Tunkar M; Morya A; Alnatsheh A; Alshamrani M; Felemban R
    Cureus; 2023 Aug; 15(8):e44267. PubMed ID: 37772227
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prospective, Multicenter Study of 5-Fluorouracil Therapeutic Drug Monitoring in Metastatic Colorectal Cancer Treated in Routine Clinical Practice.
    Wilhelm M; Mueller L; Miller MC; Link K; Holdenrieder S; Bertsch T; Kunzmann V; Stoetzer OJ; Suttmann I; Braess J; Birkmann J; Roessler M; Moritz B; Kraff S; Salamone SJ; Jaehde U
    Clin Colorectal Cancer; 2016 Dec; 15(4):381-388. PubMed ID: 27256667
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Personalized dosing via pharmacokinetic monitoring of 5-fluorouracil might reduce toxicity in early- or late-stage colorectal cancer patients treated with infusional 5-fluorouracil-based chemotherapy regimens.
    Kline CL; Schiccitano A; Zhu J; Beachler C; Sheikh H; Harvey HA; Mackley HB; McKenna K; Staveley-O'Carroll K; Poritz L; Messaris E; Stewart D; Sivik J; El-Deiry WS
    Clin Colorectal Cancer; 2014 Jun; 13(2):119-26. PubMed ID: 24461492
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Drug monitoring detects under- and overdosing in patients receiving 5-fluorouracil-containing chemotherapy-results of a prospective, multicenter German observational study.
    Li M; Mindt S; Lück A; Hutzschenreuter U; Kollendt M; Lathan B; Zöller T; Frank-Gleich S; Lorentz C; Lamberti C; Sick C; Zingerle M; Tesch H; Stein W; Hebart H; Stosiek C; Sandner R; Fries S; Burkholder I; Hofheinz RD
    ESMO Open; 2023 Apr; 8(2):101201. PubMed ID: 36965262
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A correlation study of fluorouracil pharmacodynamics with clinical efficacy and toxicity.
    Esin E; Telli TA; Yuce D; Yalcin S
    Tumori; 2018 Jun; 104(3):157-164. PubMed ID: 28708227
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Correlative analysis between serum dihydropyrimidine dehydrogenase, activity, concentration of 5-fluorouracil and adverse events in the treatment of advanced gastric cancer patients].
    Peng RJ; Dong QM; Shi YX; Cao Y; Zhou ZM; Yuan ZY; Li S; Li H; Jiang WQ
    Ai Zheng; 2006 Aug; 25(8):1039-43. PubMed ID: 16965690
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Plasma concentrations of 5-fluorouracil and F-beta-alanine following oral administration of S-1, a dihydropyrimidine dehydrogenase inhibitory fluoropyrimidine, as compared with protracted venous infusion of 5-fluorouracil.
    Yamada Y; Hamaguchi T; Goto M; Muro K; Matsumura Y; Shimada Y; Shirao K; Nagayama S
    Br J Cancer; 2003 Sep; 89(5):816-20. PubMed ID: 12942110
    [TBL] [Abstract][Full Text] [Related]  

  • 15. DPYD genotype-guided dose individualisation of fluoropyrimidine therapy in patients with cancer: a prospective safety analysis.
    Henricks LM; Lunenburg CATC; de Man FM; Meulendijks D; Frederix GWJ; Kienhuis E; Creemers GJ; Baars A; Dezentjé VO; Imholz ALT; Jeurissen FJF; Portielje JEA; Jansen RLH; Hamberg P; Ten Tije AJ; Droogendijk HJ; Koopman M; Nieboer P; van de Poel MHW; Mandigers CMPW; Rosing H; Beijnen JH; Werkhoven EV; van Kuilenburg ABP; van Schaik RHN; Mathijssen RHJ; Swen JJ; Gelderblom H; Cats A; Guchelaar HJ; Schellens JHM
    Lancet Oncol; 2018 Nov; 19(11):1459-1467. PubMed ID: 30348537
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacokinetics and pharmacodynamic effects of 5-fluorouracil given as a one-hour intravenous infusion.
    Grem JL; Quinn M; Ismail AS; Takimoto CH; Lush R; Liewehr DJ; Steinberg SM; Balis FM; Chen AP; Monahan BP; Harold N; Corse W; Pang J; Murphy RF; Allegra CJ; Hamilton JM
    Cancer Chemother Pharmacol; 2001; 47(2):117-25. PubMed ID: 11269737
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Determining the optimal 5-FU therapeutic dosage in the treatment of colorectal cancer patients.
    Fang L; Jiang Y; Yang Y; Zheng Y; Zheng J; Jiang H; Zhang S; Lin L; Zheng J; Zhang S; Zhuang X
    Oncotarget; 2016 Dec; 7(49):81880-81887. PubMed ID: 27636992
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Fluorouracil plasma monitoring: systematic review and economic evaluation of the My5-FU assay for guiding dose adjustment in patients receiving fluorouracil chemotherapy by continuous infusion.
    Freeman K; Connock M; Cummins E; Gurung T; Taylor-Phillips S; Court R; Saunders M; Clarke A; Sutcliffe P
    Health Technol Assess; 2015 Nov; 19(91):1-321, v-vi. PubMed ID: 26542268
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Fluoropyrimidine chemotherapy: recommendations for DPYD genotyping and therapeutic drug monitoring of the Swiss Group of Pharmacogenomics and Personalised Therapy.
    Hamzic S; Aebi S; Joerger M; Montemurro M; Ansari M; Amstutz U; Largiadèr C
    Swiss Med Wkly; 2020 Nov; 150():w20375. PubMed ID: 33232506
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Relationship between dihydropyrimidine dehydrogenase(DPD) activity and toxicity of 5-FU-based adjuvant chemotherapy in colorectal cancer patients].
    Zhou ZW; Wang GQ; Wan DS; Pan ZZ; Li S; Chen G; Liao H
    Ai Zheng; 2004 Nov; 23(11 Suppl):1512-6. PubMed ID: 15566669
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.